MetaCap

Immunic (IMUX) vs Sionna Therapeutics (SION)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immunic (IMUX) has outperformed Sionna Therapeutics (SION) over the past year, gaining 1.9% versus a loss of 93.5%. Sionna Therapeutics is the larger company by market cap ($127.8 million vs $111.0 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMUX+1.90%SION-93.53%
+158%+26%-106%
Nov 21, 20251 yearNov 20, 2026
IMUX-27.26%SION-88.70%
+114%+8%-98%
Feb 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMUX versus SION key metrics
MetricIMUXSION
Share price$6.99$2.83
Market cap$111.01M$127.79M
1-day change-5.41%-4.88%
YTD return+30.90%-93.13%
1-year return+1.90%-93.53%
5-year return-91.88%—
EPS (TTM)$-3.53$-2.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-97.17M$-75.27M
52-week high$17.43$54.97
52-week low$5.06$2.75
Distance from 52-week high-59.90%-94.86%
Analyst consensusstrong_buyhold
Avg. price target upside+508.73%+643.36%
Average volume343.44K1.12M
Shares outstanding15.88M45.24M
Employees10059
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMUX has outperformed SION by 95.4 percentage points over the past year.

About Immunic

IMUX stock →

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Sionna Therapeutics

SION stock →

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees

IMUX vs SION FAQ

Which is bigger, Immunic or Sionna Therapeutics?

Sionna Therapeutics (SION) is larger, with a market capitalization of $127.79M compared with $111.01M for Immunic (IMUX).

Which stock has performed better over the past year, IMUX or SION?

IMUX returned +1.90% over the past 12 months, compared with -93.53% for SION (price return, excluding dividends). Past performance does not predict future results.

Are Immunic and Sionna Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons